SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW
Status:
Not yet recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
Eighty percent of the Dutch population has completed a primary COVID-19 vaccination regimen,
and 60% of the population received a booster vaccination. Waning immunity, combined with the
emergence of antigenically distinct SARS-CoV-2 variants, has led to the consideration of
additional booster vaccinations in the Dutch population by autumn 2022. However, despite
efforts of the Dutch policymakers, the public's willingness to repeatedly receive COVID-19
booster vaccinations is declining. This is mainly due to a reduced burden of disease by
COVID-19, fewer hospitalizations, and fewer deaths. However, population immunity might be one
of the major factors responsible for this reduced burden of disease, possibly emphasizing the
need for booster vaccinations. In this proposal we will address an important question asked
by policymakers: "Are booster vaccinations in autumn recommended for the healthy population?"
Phase:
N/A
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
AUMC, University Hospital (Amsterdam, The Netherlands) LUMC, University Hospital (Leiden, The Netherlands) UMCG, University Hospital (Groningen, The Netherlands) ZonMw (Funding organisation, The Hague, The Netherlands)